Logo image of TOM2.AS

TOMTOM NV (TOM2.AS) Stock Fundamental Analysis

AMS:TOM2 - Euronext Amsterdam - NL0013332471 - Common Stock - Currency: EUR

4.82  +0.02 (+0.5%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TOM2. TOM2 was compared to 101 industry peers in the Software industry. TOM2 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TOM2 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TOM2 has reported negative net income.
In the past year TOM2 had a positive cash flow from operations.
In the past 5 years TOM2 always reported negative net income.
In multiple years TOM2 reported negative operating cash flow during the last 5 years.
TOM2.AS Yearly Net Income VS EBIT VS OCF VS FCFTOM2.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

1.2 Ratios

TOM2 has a Return On Assets of -1.30%. This is in the lower half of the industry: TOM2 underperforms 62.38% of its industry peers.
TOM2 has a Return On Equity of -6.58%. This is in the lower half of the industry: TOM2 underperforms 64.36% of its industry peers.
Industry RankSector Rank
ROA -1.3%
ROE -6.58%
ROIC N/A
ROA(3y)-5.92%
ROA(5y)-10.94%
ROE(3y)-25.16%
ROE(5y)-35.09%
ROIC(3y)N/A
ROIC(5y)N/A
TOM2.AS Yearly ROA, ROE, ROICTOM2.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 85.20%, TOM2 belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
TOM2's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TOM2 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.86%
GM growth 5Y2.76%
TOM2.AS Yearly Profit, Operating, Gross MarginsTOM2.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

TOM2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TOM2 has less shares outstanding
Compared to 5 years ago, TOM2 has less shares outstanding
TOM2 has a worse debt/assets ratio than last year.
TOM2.AS Yearly Shares OutstandingTOM2.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TOM2.AS Yearly Total Debt VS Total AssetsTOM2.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

TOM2 has a debt to FCF ratio of 18.57. This is a negative value and a sign of low solvency as TOM2 would need 18.57 years to pay back of all of its debts.
With a Debt to FCF ratio value of 18.57, TOM2 perfoms like the industry average, outperforming 43.56% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that TOM2 is not too dependend on debt financing.
The Debt to Equity ratio of TOM2 (0.22) is better than 67.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 18.57
Altman-Z N/A
ROIC/WACCN/A
WACC8.46%
TOM2.AS Yearly LT Debt VS Equity VS FCFTOM2.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

TOM2 has a Current Ratio of 1.76. This is a normal value and indicates that TOM2 is financially healthy and should not expect problems in meeting its short term obligations.
TOM2 has a better Current ratio (1.76) than 72.28% of its industry peers.
TOM2 has a Quick Ratio of 1.71. This is a normal value and indicates that TOM2 is financially healthy and should not expect problems in meeting its short term obligations.
TOM2 has a Quick ratio of 1.71. This is in the better half of the industry: TOM2 outperforms 73.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.76
Quick Ratio 1.71
TOM2.AS Yearly Current Assets VS Current LiabilitesTOM2.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

TOM2 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.19%, which is quite impressive.
TOM2 shows a decrease in Revenue. In the last year, the revenue decreased by -1.34%.
TOM2 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.90% yearly.
EPS 1Y (TTM)63.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y4.25%
Revenue growth 5Y-3.9%
Sales Q2Q%0.8%

3.2 Future

TOM2 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.79% yearly.
TOM2 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.40% yearly.
EPS Next Y-55.36%
EPS Next 2Y115.06%
EPS Next 3Y57.79%
EPS Next 5YN/A
Revenue Next Year-4.71%
Revenue Next 2Y0.02%
Revenue Next 3Y2.42%
Revenue Next 5Y7.4%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TOM2.AS Yearly Revenue VS EstimatesTOM2.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
TOM2.AS Yearly EPS VS EstimatesTOM2.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1 -1.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOM2. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 19.29, which indicates a rather expensive current valuation of TOM2.
TOM2's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TOM2 is cheaper than 75.25% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.15. TOM2 is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 19.29
TOM2.AS Price Earnings VS Forward Price EarningsTOM2.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

82.18% of the companies in the same industry are more expensive than TOM2, based on the Enterprise Value to EBITDA ratio.
TOM2's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 270.3
EV/EBITDA 8.49
TOM2.AS Per share dataTOM2.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TOM2's earnings are expected to grow with 57.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y115.06%
EPS Next 3Y57.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TOM2!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TOMTOM NV

AMS:TOM2 (5/30/2025, 7:00:00 PM)

4.82

+0.02 (+0.5%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)04-15 2025-04-15/bmo
Earnings (Next)07-15 2025-07-15
Inst Owners22.75%
Inst Owner ChangeN/A
Ins Owners53.12%
Ins Owner ChangeN/A
Market Cap602.50M
Analysts45
Price Target5.36 (11.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.63%
Min Revenue beat(2)3.11%
Max Revenue beat(2)4.14%
Revenue beat(4)3
Avg Revenue beat(4)2.37%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)4.14%
Revenue beat(8)4
Avg Revenue beat(8)0.3%
Revenue beat(12)7
Avg Revenue beat(12)2.97%
Revenue beat(16)7
Avg Revenue beat(16)1.12%
PT rev (1m)-2.33%
PT rev (3m)-3.23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-286.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.29
P/S 1.05
P/FCF 270.3
P/OCF 38.46
P/B 4.21
P/tB N/A
EV/EBITDA 8.49
EPS(TTM)-0.09
EYN/A
EPS(NY)0.25
Fwd EY5.18%
FCF(TTM)0.02
FCFY0.37%
OCF(TTM)0.13
OCFY2.6%
SpS4.6
BVpS1.14
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.3%
ROE -6.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.2%
FCFM 0.39%
ROA(3y)-5.92%
ROA(5y)-10.94%
ROE(3y)-25.16%
ROE(5y)-35.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.86%
GM growth 5Y2.76%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 18.57
Debt/EBITDA 1.48
Cap/Depr 42.98%
Cap/Sales 2.33%
Interest Coverage N/A
Cash Conversion 72.51%
Profit Quality N/A
Current Ratio 1.76
Quick Ratio 1.71
Altman-Z N/A
F-Score8
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)20.27%
Cap/Depr(5y)16.21%
Cap/Sales(3y)1.63%
Cap/Sales(5y)1.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y-55.36%
EPS Next 2Y115.06%
EPS Next 3Y57.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y4.25%
Revenue growth 5Y-3.9%
Sales Q2Q%0.8%
Revenue Next Year-4.71%
Revenue Next 2Y0.02%
Revenue Next 3Y2.42%
Revenue Next 5Y7.4%
EBIT growth 1Y64.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.57%
EBIT Next 3Y60.98%
EBIT Next 5YN/A
FCF growth 1Y118.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y334.96%
OCF growth 3Y-66.75%
OCF growth 5Y-57.16%